Editorial brief continued
billion, up 13.6% ye
- Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a year earlier.
- The quarter was highlighted by 47.3% year-over-year growth in Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue to $195.9 million, reflecting accelerating adoption of the company's next-generation structural heart devices.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? Laiba Immad Tue, July 28, 2026 at 5:20 AM GMT+9 4 min read EW On July 23, Edwards Lifesciences Corporation (NYSE: EW ) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a year earlier.
Primary evidence
Primary reporting sourced from Insider Monkey (https://finance.yahoo.com/healthcare/articles/edwards-lifesciences-ew-tmtt-revenue-202027954.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant CORPORATE EARNINGS development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for $EW.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for $EW.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for $EW amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in $EW.
[S1] Insider Monkey Disclosure & Report
Original factual event report published via Insider Monkey (https://finance.yahoo.com/healthcare/articles/edwards-lifesciences-ew-tmtt-revenue-202027954.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.